August 17, 2012 — Jarvik Heart Inc., a privately held company that develops and manufactures cardiac assist devices, announced U.S. Food and Drug Administration (FDA) approval of its pivotal trial for evaluation of the Jarvik 2000 heart for destination therapy (DT), named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD [ventricular assist device] Effectiveness).

August 17, 2012 — Siemens Healthcare announced an agreement to enhance the syngo Workflow radiology information system (RIS) by incorporating eXposure, a comprehensive radiation dose management and reporting solution from Toronto-based Radimetrics.

August 15, 2012 — Sound Interventions Inc. has released three-month data from the company's first-in-human clinical study (SOUND-ITV) to treat resistant hypertension through the use of catheter-based ultrasound.

August 15, 2012 — Previously unreleased three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease indicate that Cook Medical’s paclitaxel-eluting peripheral vascular stent demonstrated 83 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479-patient study.

TAVR, EVAR Vascular Closure Device May Eliminate Need for Surgical Cut-Down
TAVR, EVAR Vascular Closure Device May Eliminate Need for Surgical Cut-Down
TAVR, EVAR Vascular Closure Device May Eliminate Need for Surgical Cut-Down
TAVR, EVAR Vascular Closure Device May Eliminate Need for Surgical Cut-Down

Due to the increasing number of transcatheter aortic valve replacements (TAVR) and endovascular aneurysm repair (EVAR), a new startup company has developed a transfemoral combined access and closure system to accomodate these larger sized percutaneous devices and arteriotomies. 

August 14, 2012 — Berlin Heart announced that a study recently published in the New England Journal of Medicine (NEJM) concluded that survival using the Excor pediatric ventricular assist device (VAD) is "significantly greater" than the standard-of-care (extracorporeal membrane oxygenation, or ECMO) as a bridging therapy for children in need of a heart transplant.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now